首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 肥胖症治療 > 肥胖症的臨床管理：全球的產品、技術、以及市場（2011年∼2019年）
產業/市場分類
製藥 (4816)
肥胖症治療 (44)
非專利藥 (129)
疫苗 (181)
神經疾病 (172)
骨頭疾病治療 (37)
動物用醫藥 (17)
處方藥 (156)
規章 (126)
感染疾病 (346)
精神病 (84)
製藥企業 (524)
糖尿病 (191)
癌症 (909)
藥物開發 (1449)
DDS (182)
OTC 非處方藥 (150)
市場調查報告書

肥胖症的臨床管理：全球的產品、技術、以及市場（2011年∼2019年）

Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019

出版商 MedMarket Diligence
出版日期 2011年02月 商品編碼 139886
內容資訊 英文 302 Pages
價格
US $ 2950 Hard Copy
US $ 2950 PDF by E-mail ( Single User License)
US $ 3150 PDF by E-mail (Single User License) & Hard Copy
US $ 4450 PDF by E-mail (Site License)
US $ 5450 PDF by E-mail (Global License)


肥胖症的臨床管理：全球的產品、技術、以及市場（2011年∼2019年） 是由出版商MedMarket Diligence在2011年02月所出版的。 這份英文市場調查報告書包含302 Pages 價格從美金2950起跳。

簡介

本報告，彙整肥胖症臨床管理上的技術動向、產品概要，並加上現在的肥胖病患人口、2011年至2019年的市場發展預測、以及主要企業的市佔率，由下列摘要形式闡述。

報告摘要

第1章 肥胖症的臨床背景

  • 肥胖症的臨床診斷
  • 肥胖的影響
  • 能量平衡的代謝管道
  • 體重過重與肥胖的共病症
  • 全球的肥胖症罹患率與病患數

第2章 肥胖症的影響

  • 肥胖與共病症的治療成本
  • 對商業的影響
  • 預防與減重的立法

第3章 針對體重過重與肥胖治療的臨床方式

  • 行為改變與生活方式改變所扮演的角色
  • 非處方減重產品
  • 肥胖症的投藥治療：過去、現在、未來的治療藥物
  • 肥胖症的非投藥治療

第4章 市場評價

  • 影響市場預測的近期發展
  • 全球的肥胖治療市場
  • 主要企業的市佔率
  • 南北美的肥胖治療市場
  • 歐洲的肥胖治療市場
  • 亞太地區的肥胖治療市場
  • 其他區域的肥胖治療市場
  • 全球肥胖治療市場的策略

第5章 企業檔案資料

第6章 臨床實驗

附錄：企業名錄

目錄

Abstract

This report is a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity (bariatrics). The report describes the current and projected patient population in obesity, detailing their incidence worldwide, with available incidence by country for the U.S., major European countries, major countries in Asia/Pacific (including Japan, China, India and Australia), the clinical practices in their management to encompass surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. The report describes clinical trends in the management of the obese. The report details the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy and other therapies under development, and will provide current and worldwide market forecasts (2009-2019) separately for pharmaceuticals (with separate segment forecast data for satiety, malabsorption, appetite suppression and combination drugs) and devices (with separate segment forecast data for stomach restriction artificial fullness, malabsorption, gastric emptying and appetite suppression), with current (2009) market shares of the leading competitors in each segment. The report profiles the 45 leading competitors, detailing current and potential position in the market, their products and their market strengths and likelihood of future success.

Methodology

MedMarket Diligence Reports are produced through primary and secondary research. Data is gathered from published sources on products and technologies on the market and under development. Clinicians and industry representatives are interviewed for their knowledge and insights on product development, market development, clinical practice and trends associated with the evolving use of technologies. Secondary data is used to corroborate and support assessments and projections. Reports are written and researched by industry insiders, whose familiarity with the companies, industry dynamics and other marketplace specifics facilitate the research process and ensure high quality and thorough reports.

Report Statistics

  • 304 pages
  • 79 Exhibits
  • 46 Company Profiles

Table of Contents

EXECUTIVE SUMMARY

SECTION 1: CLINICAL BACKGROUND OF OBESITY

  • 1.1 Clinical Diagnosis of Obesity
    • 1.1.1 Body Mass Index Scale
    • 1.1.2 Measuring BMI vs. Measuring Adiposity
    • 1.1.3 Classification of Obesity
    • 1.1.4 Overweight, Obesity, Morbid Obesity, Super Obesity
    • 1.1.5 Genetic Testing for Obesity
  • 1.2 Obesogenic Influences
    • 1.2.1 Dietary Changes Over the Last Twenty Years
    • 1.2.2 Sedentary Lifestyles
    • 1.2.3 Ongoing Research into Causes
  • 1.3 Metabolic Pathways of Energy Homeostasis
    • 1.3.1 Role of the Hypothalamus
    • 1.3.2 Role of the Stomach
    • 1.3.3 Role of the Small Intestine
    • 1.3.4 Role of the Pancreas
    • 1.3.5 Role of Adipose Tissue, An Endocrine Organ
    • 1.3.6 Other Peptides
    • 1.3.7 Obesity as Survival Mechanism
  • 1.4 Co-Morbidities of Overweight and Obesity
    • 1.4.1 Metabolic Syndrome
    • 1.4.2 Effects of Obesity on Immune Function
    • 1.4.3 Racial Differences in Co-morbidities
    • 1.4.4 Type 2 Diabetes and Insulin Resistance
    • 1.4.5 Hypertension
    • 1.4.6 Dyslipidemia
    • 1.4.7 Depression
    • 1.4.8 Osteoarthritis
    • 1.4.9 Asthma
    • 1.4.10 Sleep apnea
    • 1.4.11 Obesity and Cancer
  • 1.5 Global Incidence and Prevalence of Obesity
    • 1.5.1 By Geographic Region
      • 1.5.1.1 USA, Canada, Mexico, Brazil
      • 1.5.1.2 European Union
      • 1.5.1.3 Asia-Pacific
    • 1.5.2 By Age Group
      • 1.5.2.1 Incidence and Prevalence among Children
      • 1.5.2.2 Incidence and Prevalence among Elderly
    • 1.5.3 Incidence and Prevalence of Morbid Obesity

SECTION 2: THE IMPACT OF OBESITY

  • 2.1 Costs Related to Treating Obesity and Co-Morbidities
    • 2.1.1 Current Healthcare Expenses
      • 2.1.1.1 Spending in the USA
      • 2.1.1.2 Outside of the U.S., Spending Also Rising
    • 2.1.2 The Looming Wave of Type 2 Diabetes
  • 2.2 Impact on Businesses
    • 2.2.1 Increased Health and Life Insurance Costs
    • 2.2.2 Increased Costs Shouldered by Employers
    • 2.2.3 Debate: Pay Employees to Lose Weight?
  • 2.3 Legislating Prevention and Weight Loss
    • 2.3.1 Healthcare Reform and Obesity
    • 2.3.2 Changing Society
    • 2.3.3 Pressure on the Food Industry

SECTION 3: CLINICAL APPROACHES TO THE TREATMENT OF OVERWEIGHT AND OBESITY

  • 3.1 Role of Behavior Modification and Lifestyle Changes
    • 3.1.1 Behavior Modification with Pharmacotherapies
    • 3.1.2 Specialists' Use of Pharmaceuticals
    • 3.1.3 Medically Supervised Low Calorie and Very Low Calorie Diets (LCDs and VLCDs)
    • 3.1.4 Why Diets Usually Fail
    • 3.1.5 The Diogenes Study' s Dietary Recommendations
  • 3.2 Non Prescription Weight Loss Products
  • 3.3 Pharmaceutical Treatment of Obesity: Past, Present and Future Drugs
    • 3.3.1 The US FDA' s Guidance for Industry Developing Products for Weight Management
    • 3.3.2 Definition of Satiety vs. Appetite Suppression
    • 3.3.3 Definition of Combination Drugs
    • 3.3.4 The Bloom is Off the Rose: Promising Drugs Which Have Failed, and Why
      • 3.3.4.1 Phentermine/Fenfluramine Combination
      • 3.3.4.2 Abbott' s Meridia (Sibutramine)
      • 3.3.4.3 Vivus' Qnexa: Out for Good?
      • 3.3.4.4 Arena' s Lorqess: Not out of the picture yet
    • 3.3.5 Prescription Drugs Currently on the Market
      • 3.3.5.1 Appetite Suppression Drugs
      • 3.3.5.2 Malabsorption Drugs
      • 3.3.5.3 Satiety Drugs
      • 3.3.5.4 Combination Drugs
    • 3.3.6 Areas of Pharmaceutical Research
      • 3.3.6.1 Melanocortin Receptor System
      • 3.3.6.2 Cannabinoid Receptor Antagonists
      • 3.3.6.3 GLP-1 Analogs
      • 3.3.6.4 Methionine Aminopeptidase 2 (MetAP2) Inhibitor
      • 3.3.6.5 Appetite Suppression Drugs
      • 3.3.6.6 Malabsorption Drugs
      • 3.3.6.7 Satiety Drugs
      • 3.3.6.8 Combination Drugs
    • 3.3.7 Safety: The Major Diet Drug Hurdle
  • 3.4 Non- Pharmaceutical Options for Treating Obesity
    • 3.4.1 Metabolic/Bariatric Surgery
      • 3.4.1.1 Buchwald and Oien Research, 2009
      • 3.4.1.2 Vertical Banded Gastroplasty
      • 3.4.1.3 Roux-en-Y Surgery
      • 3.4.1.4 Sleeve Gastrectomy
      • 3.4.1.5 Biliopancreatic Diversion with Duodenal Switch
      • 3.4.1.6 Jejuno-ileal Bypass: An Obsolete Procedure
    • 3.4.2 Devices to Treat Obesity
      • 3.4.2.1 Restrictive Devices
      • 3.4.2.2 Artificial Fullness Devices
      • 3.4.2.3 Malabsorption Devices
      • 3.4.2.4 Devices to Control Gastric Emptying
      • 3.4.2.5 Appetite Suppressive Devices
      • 3.4.2.6 Gastric Electrical Stimulation

SECTION 4: MARKET ASSESSMENT

  • 4.1 Recent Developments Impacting Market Forecasts
  • 4.2 Anticipated Developments Underlying the Market Forecast
  • 4.3 Global Market for Obesity Treatments
    • 4.3.1 Pharmaceuticals
    • 4.3.2 Devices
  • 4.4 Market Shares of Leading Companies
    • 4.4.1 Leading Pharmaceutical Companies
    • 4.4.2 Leading Device Companies
  • 4.5 Americas Market for the Treatment of Obesity
    • 4.5.1 USA
    • 4.5.2 Canada
    • 4.5.3 Mexico
    • 4.5.4 Brazil
  • 4.6 European Market for the Treatment of Obesity
    • 4.6.1 United Kingdom
    • 4.6.2 Germany
    • 4.6.3 France
    • 4.6.4 Spain
    • 4.6.5 Italy
    • 4.6.6 Rest of Europe
  • 4.7 Asia-Pacific Markets for the Treatment of Obesity
    • 4.7.1 Japan
    • 4.7.2 China
    • 4.7.3 India
    • 4.7.4 Australia
  • 4.8 ROW Markets for the Treatment of Obesity
  • 4.9 Strategies in the Global Obesity Market
    • 4.9.1 Market Drivers
      • 4.9.1.1 Significant Unmet Needs
      • 4.9.1.2 The Need for a Variety of Treatment Options
      • 4.9.1.3 Device Opportunity Grows Due to Lack of Drugs
      • 4.9.1.4 Healthcare Reform
      • 4.9.1.5 Treating Obesity to Avoid Costly Co-Morbidities
    • 4.9.2 Market Restraints
      • 4.9.2.1 Intense Complexity of the Metabolic Regulatory System
      • 4.9.2.2 Time, Costs, Risks Involved in Developing a More Efficacious Drug
      • 4.9.2.3 Tightening of Safety Requirements for Obesity Drugs
      • 4.9.2.4 Data Showing Lack of Sustainable Weight Loss with Gastric Banding
      • 4.9.2.5 Lack of Reimbursement
    • 4.9.3 Strategies for Market Success

SECTION 5: COMPANY PROFILES

  • 5.1 7TM Pharma
  • 5.2 Abbott Laboratories
  • 5.3 Allergan
  • 5.4 Amylin Pharmaceuticals
  • 5.5 Arena Pharmaceuticals
  • 5.6 AstraZeneca
  • 5.7 BAROnova Therapeutics
  • 5.8 BaroSense
  • 5.9 BFKW, LLC (c/o Legacy Capital Advisors, LLC)
  • 5.10 Covidien
  • 5.11 CR Bard, Inc.
  • 5.12 Crospon, Inc.
  • 5.13 Eli Lilly & Company
  • 5.14 EndoGastric Solutions
  • 5.15 EndoSphere
  • 5.16 EnteroMedics, Inc.
  • 5.17 Ethicon Endo-Surgery, Inc. (JNJ)
  • 5.18 Gelesis, Inc.
  • 5.19 GI Dynamics
  • 5.20 GlaxoSmithKline
  • 5.21 Helioscopie
  • 5.22 Interleukin Genetics
  • 5.23 IntraPace
  • 5.24 Laboratoire Endalis
  • 5.25 Merck
  • 5.26 MetaCure
  • 5.27 Nestle Healthcare Nutrition
  • 5.28 NeuroSearch A/S
  • 5.29 Novo Nordisk
  • 5.30 Orexigen Therapeutics, Inc.
  • 5.31 Pfizer, Inc.
  • 5.32 ReShape Medical
  • 5.33 Rhythm Pharmaceuticals
  • 5.34 SafeStitch Medical, Inc.
  • 5.35 Sanofi-Aventis
  • 5.36 Satiety, Inc.
  • 5.37 Scientific Intake, LLC
  • 5.38 Shionogi & Co., Ltd.
  • 5.39 Silhouette Medical, Inc.
  • 5.40 Spatz FGIA, Inc.
  • 5.41 Surface Logix, Inc.
  • 5.42 USGI Medical
  • 5.43 ValenTx, Inc.
  • 5.44 Verva Pharmaceuticals Ltd.
  • 5.45 Vivus, Inc.
  • 5.46 Zafgen, Inc.

SECTION 6: CLINICAL TRIALS

APPENDIX: COMPANY DIRECTORY

List of Exhibits

  • Exhibit ES-1: Estimated Overweight & Obesity (BMI > 25 kg/m2) Prevalence, Males, Aged 15+, 2010
  • Exhibit ES-2: Past and Projected Future Overweight Rates in Selected O.E.C.D. Countries
  • Exhibit ES-3: Global Market for Treatment of Obesity, 2009-2019 (USD millions)
  • Exhibit ES-4: Regional Percent Revenue Shares, 2009
  • Exhibit ES-5: Manufacturer Percent Revenue Shares, Global Obesity Market, 2009
  • Exhibit 1-1: Calculation of Body Mass Index (BMI)
  • Exhibit 1-2: Proposed WHO Classification of BMI in Adult Asians
  • Exhibit 1-3: The International BMI Classification of Adult Underweight, Overweight and Obesity According to the World Health Organization (WHO)
  • Exhibit 1-4: The Human Gastrointestinal Tract
  • Exhibit 1-5: From Chronic Energy Imbalance to Co-Morbidities
  • Exhibit 1-6: Relative Risk of Mortality by BMI in US Men
  • Exhibit 1-7: Relative Risk of Mortality by BMI in US Women
  • Exhibit 1-8: World Incidence and Prevalence for Cancers Associated with Obesity
  • Exhibit 1-9: AICR Estimated Cases Per Year of Cancers Linked to Excss Body Fat
  • Exhibit 1-10: Populations and Rates of Obesity of Selected Countries, 2009
  • Exhibit 1-11: Estimated Overweight & Obesity (BMI > 25 kg/m2) Prevalence, Males, Aged 15+, 2010
  • Exhibit 1-12: Past and Projected Future Overweight Rates in Selected O.E.C.D. Countries
  • Exhibit 1-13: Percent of Adults Who are Overweight/Obese, by Country, 2010
  • Exhibit 1-14: USA Obesity Prevalence by State, 2004.
  • Exhibit 1-15: USA Obesity Prevalence by State, 2009.
  • Exhibit 1-16: Prevalence of Obesity in Canada for 1978-2005 (Measured Values)
  • Exhibit 1-17: Prevalence of Overweight and Obesity in Women and Men in Mexico from a Nationally Representative Sample and a Sample of Low-Income Rural Mexicans
  • Exhibit 1-18: WHO Prevalence of Obesity by Sex, Adults Aged 15 and Over, Latest Available Year, Europe
  • Exhibit 1-19: States of India ranked by percentage of overweight or obese (2006)
  • Exhibit 1-20: Percent of Children in Select Age Groups and Countries Who are Overweight (Including Obese), 2010
  • Exhibit 3-1: FDA List of Tainted Weight Loss Products, March 2009
  • Exhibit 3-2: Companies with Obesity Pharmaceuticals on Market or in Development, 2010
  • Exhibit 3-3: Number Of Bariatric Surgeons and Bariatric Surgery Operations, 2008
  • Exhibit 3-4: Global Trend in Metabolic/Bariatric Surgery, 2003-2013
  • Exhibit 3-5: Global Trends in Metabolic/Bariatric Surgery, 2003-2013
  • Exhibit 3-6: Regional Trend in Metabolic/Bariatric Surgery, USA/Canada, 2003-2008
  • Exhibit 3-7: USA/Canada Trends in Metabolic/Bariatric Surgery, 2003-2013
  • Exhibit 3-8: Regional Trends in Metabolic/Bariatric Surgery, Europe, 2003-2013
  • Exhibit 3-9: European Trends in Metabolic/Bariatric Surgery, 2003-2013
  • Exhibit 3-10: Regional Trends in Metabolic/Bariatric Surgery, Asia/Pacific, 2003-2013
  • Exhibit 3-11: Regional Trends in Metabolic/Bariatric Surgery, Asia/Pacific, 2003-2013
  • Exhibit 3-12: Regional Trend in Metabolic/Bariatric Surgery, Rest of World, 2003-2013
  • Exhibit 3-13: Regional Trends in Metabolic/Bariatric Surgery, Rest of World, 2003-2013
  • Exhibit 3-14: Companies with Obesity Devices on Market or in Development, 2010
  • Exhibit 4-1: Global Market for Treatment of Obesity, 2009-2019 (USD millions)
  • Exhibit 4-2: Global Market for Treatment of Obesity, 2009-2019 (USD millions)
  • Exhibit 4-3: Total Modality Market Shares by Percent Revenues, 2009
  • Exhibit 4-4: Total Modality Market Shares by Percent Revenue, 2019
  • Exhibit 4-5: Global Markets for Pharmaceutical Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-6: Global Markets for Pharmaceutical Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-7: Global Market for Device Treatment of Obesity, 2009-2019, (USD Millions)
  • Exhibit 4-8: Global Market for Medical Device Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-9: Percent Revenue Shares, Global Obesity Market, 2009
  • Exhibit 4-10: Percent Revenue Shares, Global Anti-Obesity Drug Market, 2009
  • Exhibit 4-11: Percent Revenue Shares, Global (Off-Label) Satiety Drug Market, 2009
  • Exhibit 4-12: Percent Revenue Shares, Global Pharmaceutical Appetite Suppression Market, 2009
  • Exhibit 4-13: Percent Revenue Shares, Global Anti-Obesity Devices Market, 2009
  • Exhibit 4-14: Percent Revenue Shares, Global Restrictive Devices Market, 2009
  • Exhibit 4-15: Percent Revenue Shares, Global Artificial Fullness Devices Market, 2009
  • Exhibit 4-16: Percent Revenue Shares, Global Appetite Suppression Devices Market, 2009
  • Exhibit 4-17: Americas Market for Treatment of Obesity, 2009-2019
  • Exhibit 4-18: Americas Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-19: USA Market for Treatments of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-20: Canada Market for Treatments of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-21: Mexico Market for Treatments of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-22: Brazil Market for Treatments of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-23: European Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-24: EU Obesity Percent Revenue Market Shares by Country, 2009
  • Exhibit 4-25: EU Obesity Percent Revenue Market Shares by Country, 2019
  • Exhibit 4-26: European Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-27: UK Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-28: Trends in Gastric Bypass vs. Gastric Banding, England, 2000-2007
  • Exhibit 4-29: Germany Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-30: France Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-31: Spain Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-32: Italy Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-33: Rest of Europe Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-34: Asia-Pacific Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-35: Asia-Pacific Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-36: Japan Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-37: China Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-38: India Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-39: Australia Market for Treatment of Obesity, 2009-2019 (USD Millions)
  • Exhibit 4-40: Rest of World Market for Treatment of Obesity, 2009-2019 (USD Millions)
Back to Top